Skip to main content
AARD
NASDAQ Life Sciences

Aardvark Therapeutics Awards $703.5K in Retention Bonuses to CFO/COO and CMO Amidst Clinical Hold

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$3.9
Mkt Cap
$85.084M
52W Low
$3.35
52W High
$17.94
52W Position info
16% above low
Off High info
78% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

AARD sits 16% above its 52-week low of $3.35.

Summary

Aardvark Therapeutics is paying over $700,000 in retention bonuses to its CFO/COO and CMO to secure their continued employment during a critical period marked by clinical trial pauses, an FDA clinical hold, and a securities fraud investigation.


Key Events · Executive and Board Changes · AARD

  • CFO/COO Retention Bonus

    Nelson Sun, the Chief Financial Officer and Chief Operating Officer, will receive a $346,500 cash retention bonus, comprising a guaranteed 2026 annual bonus of $198,000 and a retention bonus of $148,500.

  • CMO Retention Bonus

    Manasi Jaiman, M.D., M.P.H., the Chief Medical Officer, will receive a $357,000 cash retention bonus, comprising a guaranteed 2026 annual bonus of $204,000 and a retention bonus of $153,000.

  • Leadership Stability Amidst Crisis

    These bonuses are intended to retain key C-suite executives through January 1, 2027, or provide severance, during a period of significant company distress, including a full clinical hold on its lead drug and a securities fraud investigation.

  • Significant Compensation Relative to Market Cap

    The total bonuses of $703,500 are substantial for a company with an approximate $85 million market capitalization, underscoring the company's efforts to maintain leadership amidst its challenges.


Analysis · AARD · Life Sciences

Aardvark Therapeutics is providing substantial cash retention bonuses to its Chief Financial Officer/Chief Operating Officer and Chief Medical Officer. This move aims to stabilize key leadership during a period of significant operational challenges, including a full clinical hold on its lead drug candidate, trial pauses, and a securities fraud investigation. The bonuses are designed to ensure continuity of management through at least January 1, 2027, or provide severance if employment is terminated without cause or for good reason.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AARD was trading at $3.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $85.1M. The 52-week trading range was $3.35 to $17.94. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AARD - Latest Insights

AARD
Nov 13, 2026, 8:18 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.52
Real-time Price: $0.929916 info
Change: -$0.589784 (-39%) info
Market Cap: $19.921M info
AARD
Nov 13, 2026, 7:47 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $1.52
Real-time Price: $0.929916 info
Change: -$0.590084 (-39%) info
Market Cap: $19.921M info
AARD
Nov 12, 2026, 7:56 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.51
Real-time Price: $0.929916 info
Change: -$0.580084 (-38%) info
Market Cap: $19.921M info
AARD
Oct 23, 2026, 8:38 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.09
Real-time Price: $0.929916 info
Change: -$2.16 (-70%) info
Market Cap: $19.921M info
AARD
Oct 22, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.95
Real-time Price: $0.929916 info
Change: -$3.02 (-76%) info
Market Cap: $19.921M info